| 1.26 0 (0%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.53 | 1-year : | 1.78 |
| Resists | First : | 1.3 | Second : | 1.53 |
| Pivot price | 1.19 |
|||
| Supports | First : | 1.13 | Second : | 1.02 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.17 |
| MA(100) : | 1.76  |
MA(250) : | 2.95 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 79.2 |
| RSI | RSI(14): 58 | |||
| 52-week | High : | 6.92 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SNOA ] has closed below upper band by 18.0%. Bollinger Bands are 68.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.21 - 1.22 | 1.22 - 1.23 |
| Close: | 1.25 - 1.26 | 1.26 - 1.27 |
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Fri, 10 Jul 2026
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Thu, 09 Jul 2026
Sonoma Pharmaceuticals (SNOA) CFO receives 10,000 RSU equity award in new grant - Stock Titan
Thu, 09 Jul 2026
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Thu, 09 Jul 2026
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Tue, 30 Jun 2026
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.98 |
| Profit Margin | -16.3 % |
| Operating Margin | -6.4 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -84.6 % |
| Qtrly Rev. Growth | 48 % |
| Gross Profit (p.s.) | 1.54 |
| Sales Per Share | 4.07 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 1 |
| Price to Book value | 0.63 |
| Price to Sales | 0.3 |
| Price to Cash Flow | -1.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|